SCHEMBL6437239

SCHEMBL6437239

Cc1cccc(NC(=O)Nc2ccc(-c3nn(CCCC(N)=O)c4ncnc(N)c34)cc2F)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 16/20 0.66
▸ PDGFRB P09619 4/20 0.66
▸ HDAC1 Q13547 4/20 0.66
▸ AURKA O14965 2/20 0.60
▸ AURKB Q96GD4 2/20 0.60
▸ IKBKE Q14164 1/20 0.60
▸ FLT3 P36888 7/20 0.57
▸ KIT P10721 7/20 0.57
▸ RIPK1 Q13546 1/20 0.49
▸ TEK Q02763 3/20 0.49
▸ FGFR1 P11362 3/20 0.48
▸ LCK P06239 2/20 0.48
▸ RET P07949 2/20 0.48
▸ SYK P43405 2/20 0.48
▸ BLK P51451 2/20 0.48
▸ MAP4K5 Q9Y4K4 2/20 0.48
▸ PDPK1 O15530 1/20 0.48
▸ DAPK3 O43293 1/20 0.48
▸ PRKD3 O94806 1/20 0.48
▸ PDGFRA P16234 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5803692 0.92 KDR (0.62) KDRPDGFRBHDAC1AURKAAURKB
SCHEMBL5801797 0.85 AURKA (0.57) KDRPDGFRBHDAC1AURKAAURKB
SCHEMBL7702164 0.84 AURKA (0.56) KDRPDGFRBHDAC1AURKAAURKB
SCHEMBL15978893 0.83 RET (0.62) KDRPDGFRBHDAC1AURKAAURKB
SCHEMBL5804211 0.83 AURKB (0.59) KDRPDGFRBHDAC1AURKAAURKB
SCHEMBL5801783 0.82 AURKB (0.53) KDRPDGFRBHDAC1AURKAAURKB
SCHEMBL5823907 0.82 AURKA (0.58) KDRPDGFRBHDAC1AURKAAURKB
SCHEMBL12120731 0.82 KDR (0.79) KDRPDGFRBHDAC1AURKAAURKB
SCHEMBL5802933 0.80 AURKA (0.56) KDRPDGFRBHDAC1AURKAAURKB
SCHEMBL17853708 0.80 HDAC1 (1.00) KDRPDGFRBHDAC1AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6921763-B2 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2005-07-26 — — US disclosed
US-20050008640-A1 Method of treating transplant rejection ABBOTT LABORATORIES 2005-01-13 — — US disclosed
US-6660744-B1 Kinase inhibitors ABBOTT GMBH & CO. KG (DE) 2003-12-09 — — US disclosed
EP-1212327-B1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AG (DE) 2003-08-20 — — EP disclosed
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2002-10-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050008640-A1 Method of treating transplant rejection LCK, ZAP70, FYN KDR 3981/4885PDGFRB 2246/4885HDAC1 327/4885
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents DPYD, CYP2D6, UGT1A1 KDR 1166/4885PDGFRB 1146/4885HDAC1 527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback